Warfare vs welfare: investing more in our defences isn’t the problem – paying for it is - COMMENT: A survey has shown that ...

BioDelivery Sciences International, Inc. BDSI has signed a definitive agreement with Collegium Pharmaceutical, Inc. COLL, wherein the latter will acquire the former in an all-cash transaction for ...

Pain drug company Collegium Pharmaceutical is broadening its scope with the acquisition of BioDelivery Sciences International, a specialty pharmaceutical company built around a technology platform ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc.

Anyone who’s ever endured a migraine knows all too well the experience of waiting for the meds to kick in and hoping the nausea isn’t so bad they are vomited up before that happens. BioDelivery ...

BioDelivery Sciences International, Inc. BDSI announced an updated financial guidance for full-year 2021. The company expects total net product revenues, including net sales of Belbuca, at the upper ...

RALEIGH – BioDelivery Sciences International (Nasdaq: BDSI) has appointed John Golubieski as the company’s chief financial officer. Golubieski will begin the CFO role on November 4, the company ...

I would now like to turn this conference over to your host, Ms. Terry Coelho, Chief Financial Officer. Thank you. You may begin. Terry Coelho-- Chief Financial Officer Thank you, and good morning, ...

RALEIGH, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious ...